Tuberculosis and Respiratory Diseases
- 제44권4호
- /
- Pages.776-784
- /
- 1997
- /
- 1738-3536(pISSN)
- /
- 2005-6184(eISSN)
수술이 불가능한 제 III기 비소세포폐암에서 Cisplatin 및 Etoposide(EP)의 화학요법과 방사선요법의 병행요법(2상 임상연구)
Phase II Study of Concurrent Chemotherapy with Etoposide and Cisplatin (EP) and Radiation Therapy for Unresectable Stage III Non-small Cell Lung Cancer
- 허남현 (원자력병원 내과) ;
- 이춘택 (원자력병원 내과) ;
- 김재학 (원자력병원 내과) ;
- 장재진 (원자력병원 내과) ;
- 남승모 (원자력병원 내과) ;
- 박연희 (원자력병원 내과) ;
- 류백렬 (원자력병원 내과) ;
- 김태유 (원자력병원 내과) ;
- 임영혁 (원자력병원 내과) ;
- 강윤구 (원자력병원 내과) ;
- 김미숙 (원자력병원 방사선 종양학과) ;
- 류성렬 (원자력병원 방사선 종양학과) ;
- 이진오 (원자력병원 내과) ;
- 강태웅 (원자력병원 내과)
- Hur, Nam-Hyun (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Lee, Choon-Taek (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Kim, Jae-Hag (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Jang, Jae-Jin (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Nam, Seung-Mo (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Park, Yeon-Hee (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Ryoo, Baek-Yeol (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Kim, Tae-You (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Im, Young-Hyuck (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Kang, Yoon-Koo (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Kim, Mi-Sook (Department of Radiation Oncology, Korea Cancer Center Hospital) ;
- Yoo, Seong-Yul (Department of Radiation Oncology, Korea Cancer Center Hospital) ;
- Lee, Jhin-Oh (Department of Internal Medicine, Korea Cancer Center Hospital) ;
- Kang, Tae-Woong (Department of Internal Medicine, Korea Cancer Center Hospital)
- 발행 : 1997.08.31
초록
서 론 : 비소세포폐암은 전체 폐암의 약 75%를 차지하고 있으며 조기 발견에 이은 외과적 절제가 유일한 완치방법으로 알려져 있다. 그러나 병기 III기에서는 정립된 치료방법이 없고 여러 종류 및 조합의 치료방법이 시도되고 있다. 이에 연구자들은 수술이 불가능한 병기 IIIA 및 악성흉수를 제외한 병기 IIIB의 과거 치료력이 없는 비소세포폐암 환자에서 cisplatin, etoposide 이용한 복합화학요법을 동시에 시행하여 그의 효과 및 순응성을 조사하였다. 대상 및 방법 : 1995년 10월부터 1996년 12월까지 원자력병원에 입원하여 조직학적으로 비소세포폐암으로 진단된 병기 III기의 환자중 수술이 불가능한 IIIA 및 IIIB의 환자를 대상으로 하였다. 복합화학요법은 cisplatin 30mg/
Background : Various combinations of treatment modalities have been reported in stage III non-small cell lung cancer (NSCLC). however, the standard treatment modality has not established yet. Recently, the efficacy of concurrent chemotherapy and radiation therapy has been reported in locally advanced lung cancer. We evaluate the response rate, toxicity, and survival of concurrent chemotherapy with etoposide and cisplatin(EP) and radiation therapy for unresectable stage III NSCLC. Method : Between October 1995 and December 1996, 32 patients with histologically proven unresectable stage III NSCLC without malignant pleural effusion were entered into this study. Twenty-nine patients were eligible for the response, survival, and toxicity analysis. Induction was two cycles of chemotherapy with etoposide and cisplatin plus concurrent chest RT to 4500cGy. Resection was attempted if the clinical response offered surgical resectability. Boost radiation therapy upto 5940cGy and one cycle of EP were performed if the disease were stable or responsive but still unresectable. Results : Of 29 eligible patients, 22(75.9%) showed partial response(PR). The progression free interval was 6.3months(range 1.1 to 19.5months). Surgical resection was performed in one patient. The median survival was 12.1months and one-year survival rate was 50.6%. The major toxicity was leukopenia(
키워드